HOLDINGS

# Fiscal 2018 Supplementary Material 

## POLA ORBIS HOLDINGS INC.

## Representative Director and President Satoshi Suzuki

1. Highlights of Consolidated Performance
2. Segment Analysis
3. Progress of Mid-term Management Plan
4. Forecasts and Initiatives for Fiscal 2019
5. Appendices

## Cosmetics Market

■ Japanese cosmetics market including exports showed steady growth; however, a slowdown trend in inbound consumption is observed since September and the same situation continues up to the present.

- Excluding inbound demand, it is assumed that the size of the Japanese domestic market is shrinking.
*Source: Ministry of Economy, Trade and Industry, Japan Department Stores Association, Ministry of Internal Affairs and Communications, Intage SLI


## Our Group

■ The Group achieved increases both in sales and operating income for nine consecutive years being driven by POLA.

- POLA was affected by the trend of inbound and buyers; however, the brand successfully expanded its customer base in Japan.
■ ORBIS launched new "ORBIS U" and realized an increase in operating income thanks to initiatives focused on brand appeal.
■ Jurlique continued to struggle and incurred an impairment loss.
- As for brands under development, THREE continued to expand both in Japan and overseas and new brands were off to a good start.

| (Reference) Ratio of Inbound Sales |  |
| :---: | :---: |
| to Consolidated Net Sales |  |
| FY2016 (Full year) | Approx. 6\% |
| FY2017 (Full year) | Approx. 7\% |
| FY2018 (Full year) | Approx. 7\% |



## POLA ORBIS <br> HOLDINGS

| (mil. yen) | FY2017 <br> Results | FY2018 <br> Results | YoY Change |  | vs. Plan (Nov 26, 2018) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Amount | \% | Amount | \% |
| Consol. net sales | 244,335 | 248,574 | 4,239 | 1.7\% | $(4,425)$ | (1.7\%) |
| Operating income | 38,881 | 39,496 | 615 | 1.6\% | $(2,003)$ | (4.8\%) |
| Ordinary income | 39,250 | 38,954 | (295) | (0.8\%) | $(2,545)$ | (6.1\%) |
| Profit attributable to owners of parent | 27,137 | 8,388 | $(18,749)$ | (69.1\%) | $(12,711)$ | (60.2\%) |
| Average exchange rates: 1.00 AUD $=82.59 \mathrm{JPY}, 1.00 \mathrm{USD}=110.43 \mathrm{JPY}, 1.00 \mathrm{CNY}=16.71 \mathrm{JPY}$ |  |  |  |  |  |  |
|  | Variance from Nov 26 Plan | Major Factors of the Variance |  |  |  |  |
| Consol. net sales | $\begin{array}{r} -¥ 4,425 \text { mil. } \\ (-1.7 \%) \end{array}$ | ■ POLA (approx. $+¥ 1,200$ mil.) Jurlique (approx. $-¥ 3,600$ mil.) <br> ■ ORBIS (approx. $-¥ 2,600$ mil.) (approx under development $+¥ 1,000$ mil.) |  |  |  |  |
| Operating income | $\begin{array}{r} -¥ 2,003 \text { mil. } \\ (-4.8 \%) \end{array}$ | Increase in gross profit and improved cost efficiencies at POLA (approx. $+¥ 1,600$ mil.) <br> - Improved efficiency of promotion expenses at ORBIS (approx. $+¥ 300$ mil.) Decrease in gross profit and allowance for doubtful accounts related to delayed receivables at Jurlique (approx. - $¥ 3,700$ mil.) |  |  |  |  |
| Ordinary income | $\begin{array}{r} -¥ 2,545 \text { mil. } \\ (-6.1 \%) \end{array}$ | In addition to a decrease in operating income, FX losses incurred (approx. - $¥ 600$ mil.) |  |  |  |  |
| Profit attributable to owners of parent | $\begin{array}{rl} -¥ 12,711 & \mathrm{mil} . \\ & (-60.2 \%) \end{array}$ | - Impairment loss at Jurlique (approx. - $¥ 11,300$ mil.) <br> - Extraordinary losses due to a voluntary product recall at POLA (approx. - $¥ 700$ mil.) <br> - Adjustments as a result of the closing of transfer of the pharmaceuticals business (approx. - $¥ 400$ mil.) |  |  |  |  |

Analysis of Consolidated P\&L Changes
Net Sales to Operating Income

| (mil. yen) | $\begin{aligned} & \text { FY2017 } \\ & \text { Results } \end{aligned}$ | FY2018 <br> Results | YoY Change |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | Amount | \% |
| Consolidated net sales | 244,335 | 248,574 | 4,239 | 1.7\% |
| Cost of sales | 41,632 | 41,521 | (110) | (0.3\%) |
| Gross profit | 202,703 | 207,052 | 4,349 | 2.1\% |
| SG\&A* expenses | 163,822 | 167,556 | 3,734 | 2.3\% |
| Operating income | 38,881 | 39,496 | 615 | 1.6\% |
| - Key Factors |  |  | Selling, General and | ative Expenses |

■ Consol. net sales
Sales were mostly driven by POLA, which experienced strong sales to existing customers in Japan and growth in the Chinese, Hong Kong, and duty-free markets. Sales decreased at ORBIS and Jurlique. THREE sustained favorable sales.

- Cost of sales The cost of sales ratio was improved owing to an increase in the sales composition ratio of high-prestige products under POLA and improved skincare ratio at ORBIS. Cost of sales ratio FY2017: 17.0\% $\Rightarrow$ FY2018: 16.7\%
■ SG\&A expenses Labor expenses : up $¥ 949$ mil. YoY
-> resulted from store expansion at POLA and personnel increases at new brands.
Sales commissions : up $¥ 1,812$ mil. YoY
-> resulted from increased sales at POLA. The commission ratio within POLA has improved.
Sales related expenses : down $¥ 2,478$ mil. YoY
-> reduction in advertising expenses at POLA and improved efficiency of promotion expenses at ORBIS.
Administrative expenses, etc.: up $¥ 3,450$ mil. YoY
$->$ resulted from overseas expansion of POLA, a recording of allowance for doubtful accounts at Jurlique, and new brand launches.
■ Operating income Operating margin FY2017: 15.9\% $\Rightarrow$ FY2018: 15.9\%


## EK POLA ORBIS Analysis of Consolidated P\&L Changes

HOLDINGS Operating Income to Profit Attributable to Owners of Parent

| (mil. yen) | FY2017 <br> Results | FY2018 <br> Results | YoY |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | Amount | \% |
| Operating income | 38,881 | 39,496 | 615 | 1.6\% |
| Non-operating income | 465 | 476 | 10 | 2.3\% |
| Non-operating expenses | 96 | 1,017 | 921 | 959.4\% |
| Ordinary income | 39,250 | 38,954 | (295) | (0.8\%) |
| Extraordinary income | 630 | 28 | (601) | (95.5\%) |
| Extraordinary losses | 1,450 | 22,919 | 21,468 | - |
| Profit before income taxes | 38,430 | 16,064 | $(22,366)$ | (58.2\%) |
| Income taxes | 11,281 | 7,675 | $(3,606)$ | (32.0\%) |
| Profit attributable to non-controlling interests | 11 | 0 | (10) | (95.4\%) |
| Profit attributable to owners of parent | 27,137 | 8,388 | $(18,749)$ | (69.1\%) |

Key Factors
■ Non-operating expenses : Loss from unfavorable foreign exchange rates $¥ 834$ mil.
$■$ Extraordinary losses : Impairment loss at Jurlique (goodwill, right of trademark, and other tangible and intangible fixed assets) $¥ 11,331$ mil.
Losses as a result of transfer of the pharmaceuticals business
(debt waiver, etc.) $¥ 10,056$ mil.
Losses due to a voluntary product recall at POLA $¥ 709$ mil.

Profit attributable to owners of parent was down 69.1\% yoy due to extraordinary losses


【【 HOLDINGS

1. Highlights of Consolidated Performance

2 Segment Analysis
3. Progress of Mid-term Management Plan
4. Forecasts and Initiatives for Fiscal 2019
5. Appendices

## POLA ORBIS

| (mil yen) | $\begin{aligned} & \text { FY2017 } \\ & \text { Results } \end{aligned}$ | $\begin{aligned} & \text { FY2018 } \\ & \text { Results } \end{aligned}$ | YoY |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | Amount | \% |
| Consolidated net sales | 244,335 | 248,574 | 4,239 | 1.7\% |
| Beauty care | 227,133 | 231,207 | 4,074 | 1.8\% |
| Real estate | 2,694 | 2,707 | 12 | 0.5\% |
| Others | 14,507 | 14,659 | 151 | 1.0\% |
| Operating income | 38,881 | 39,496 | 615 | 1.6\% |
| Beauty care | 38,121 | 38,294 | 173 | 0.5\% |
| Real estate | 1,082 | 1,001 | (81) | (7.5\%) |
| Others | (314) | 796 | 1,110 | - |
| Reconciliations | (8) | (596) | (587) | - |

- Segment Results Summary

■ Beauty care Sales growth was mainly attributed to POLA and brands under development.
Operating income rose $0.5 \%$ due to recording of allowance for doubtful accounts at Jurlique and new brand launches.

■ Real estate Occupancy rate has been maintained at a high level. However, maintenance expenses were incurred.

■ Others The Group withdrew from the pharmaceuticals business.
(share transfer completed on January 1, 2019)

| (mil. yen) | FY2017 <br> Results | $\begin{aligned} & \text { FY2018 } \\ & \text { Results } \end{aligned}$ | YoY Change |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | Amount | \% |
| Beauty care net sales | 227,133 | 231,207 | 4,074 | 1.8\% |
| POLA | 144,012 | 150,183 | 6,170 | 4.3\% |
| ORBIS | 53,066 | 51,051 | $(2,014)$ | (3.8\%) |
| Jurlique | 12,772 | 10,386 | $(2,385)$ | (18.7\%) |
| H2O PLUS | 2,303 | 2,041 | (261) | (11.4\%) |
| Brands under development | 14,978 | 17,544 | 2,566 | 17.1\% |
| Beauty care operating income | 38,121 | 38,294 | 173 | 0.5\% |
| POLA | 28,584 | 32,574 | 3,989 | 14.0\% |
| ORBIS | 9,080 | 9,340 | 259 | 2.9\% |
| Jurlique | (505) | $(3,763)$ | $(3,257)$ | - |
| H2O PLUS | (317) | (552) | (235) | - |
| Brands under development | 1,278 | 695 | (583) | (45.6\%) |

[^0]
## POLA

## FY2018 Result

- External factors affected the performance in the 2 H (see right), however, POLA maintained stable growth for the full year thanks to the increased number of customers.
- Overseas sales grew especially in the Chinese, Hong Kong, and duty-free markets (by 2 times).
- The inbound ratio was approximately $11 \%$.

(1) Consignment sales channel
(2) PB: POLA THE BEAUTY stores
(3) D2D: Conventional door-to-door *YOY


July - Counterfeits of Wrinkle Shot September - False article about Innnerlock October -
Strengthened customs inspection and news of e-commerce law

## Quarterly net sales (mil. yen)



Quarterly operating income (mil. yen)


Q1
Q2
Q3

Brand Analysis (2)

## FY2018 Result

■ Launched new ORBIS U in October.
■ Operating income increased by improved cost efficiency, however, restrained discount-type promotions resulted in a decrease in the number of customers.

- Successfully improved the quality of the customer structure; the brand aims to improve repeat ratio and purchase price per customer.

| Q4 | Results (mil. yen) | YoY Change |
| :---: | :---: | :---: |
| Net sales | 51,051 | (3.8\%) |
| Operating income | 9,340 | 2.9\% |
| Key indicators |  |  |
| Sales ratio | Online | 48.6\% |
|  | Other mail-order | 23.7\% |
|  | Stores and overseas | 27.7\% |
| Sales increase* | Online | down 1.0\% |
|  | Other mail-order | down 9.8\% |
|  | Stores and overseas | down 2.7\% |
| Mail-order ${ }^{(1)}$ purchase per customer* |  | up 1.6\% |
| Number of mail-order ${ }^{(1)}$ customers* |  | down 6.3\% |
| Number of customers purchasing the ORBIS U series ${ }^{\star(2)(3)}$ |  | up 51.3\% |

[^1]
## Topics

■ ORBIS U series ${ }^{(3)}$
Sales total : + 34\% yoy
Sales composition ratio : 21\%
(up 6.0pt YoY)

ORBIS U
Quarterly net sales (mil. yen)


Quarterly operating income (mil. yen)


## Jurlique

Brand Analysis (3)

## FY2018 Result

■ Sales declined by $15.3 \%$ yoy (on an AUD basis).

- Sales of the mainstay new products exceeded that of last year however, the brand continued to struggle due to a reduction in sales locations and channel optimization.
- Recorded an impairment loss in 4Q.

| Q4 | Results (mil. yen) | YoY Change ${ }^{(1)}$ |
| :---: | :---: | :---: |
| Net sales | 10,386 | (18.7\%) |
| Operating income (before goodwill amortization) | $(3,704)$ | $(3,260)$ |
| Operating income | $(3,763)$ | $(3,257)$ |
| Key indicators |  |  |
| Number of doors in China (vs. Dec. 2017) |  | 89 (down 21) |
| Sales ratio | ina | 14\% |
|  | ng Kong | 16\% |
|  | ty free | 15\% |
|  | stralia | 31\% |
| Sales growth ${ }^{(2)}$ | ina | down 38\% |
|  | ng Kong | down 7\% |
|  | ty free | down 10\% |
|  | stralia | down 17\% |

(1) For operating income, the YoY difference is shown as an amount (mil. yen).
(2) AUD basis, YoY

## Topics

■ New product that symbolizes


Herbal Recovery Signature Serum

```
Quarterly net sales (mil. yen)
```



## Performance Variance and Impairment Loss of Jurlique

## Recorded impairment loss (on goodwill, etc.) in the fourth quarter of fiscal 2018

Reasons for the recording

- In spite of the measures such as organizational changes and reform in product development system and marketing plan, it is taking time to reach the expected outcome
■ Recorded an impairment loss as a result of considering the situation where the difference between the performance plan and outlook became large for fiscal 2018



## OP income

Operating loss increased against initial plan of break-even due to the following factors:
$\checkmark$ Decrease in gross profit as a result of a decrease in sales at all channel
$\checkmark$ Recording of allowance for doubtful accounts related to delayed receivables as a temporary cost

Recorded amount and impact on future performance

FY 2018
Impairment loss : approximately $¥ 11,300$ mil.
(Goodwill of approx. $¥ 800$ mil., right of trademark of approx. $¥ 8,400$ mil. and other tangible and intangible fixed assets of approx. $¥ 2,100$ mil.)

See page 26 for initiatives going forward

FY 2019
Decrease in depreciation : approximately $¥ 350$ mil.

## H2O+

BEAUTY
Brand Analysis (4)

## FY2018 Result

■ Sales decreased due to a decrease in the number of stores that carry the brand at a retail chain.
■ Valuation loss on goods was incurred as a result of streamlining the number of products.

| Q4 | Results (mil. yen) | YoY Change ${ }^{(1)}$ |
| :---: | :---: | :---: |
| Net sales | 2,041 | (11.4\%) |
| Operating income | (552) | (235) |
| Key indicators |  |  |
| Sales ratio | North America | 87\% |
|  | Others | 13\% |
| Sales growth ${ }^{(2)}$ | North America | down 13\% |
|  | Others | up 14\% |

[^2]
## Topics

- The brand plans to debut products that are developed and manufactured by POLA CHEMICAL INDUSTREIS, INC. in 2019


Quarterly operating income (mil. yen)
Q1
Q2
Q3
Q4
201620172018201620172018201620172018201620172018


## POLA ORBIS <br> HOLDINGS

Brand Analysis (5) Brands Under Development

## FY2018 Result

- THREE strengthened customer structure by focusing on skincare and expanded overseas channel such as dutyfree and cross-border e-commerce.
- Costs for launching new brands were approx. $¥ 1.5$ bil. as planned. THREE doubled its OP income (increased by $¥ 500$ mil.) on a stand-alone basis.
- DECENCIA sustained growth driven by existing customers.

| Q4 | Results (mil. yen) | YoY Change |
| :---: | :---: | :---: |
| Net sales | 17,544 | 17.1\% |
| Operating income | 695 | (45.6\%) |
| ACRO Net sales | 10,485 | 30.6\% |
| ACRO OP income | (516) | $(1,039)$ |
| (THREE Net sales) | 10,320 | 28.6\% |
| (THREE OP income) | 1,008 | 92.9\% |
| Key indicators |  |  |
| THREE Dept. store | unters in Japan | 41 |
| Other store | Japan | 70 |
| Overseas s | S (in 7 countries \& regions) | 55 |
| Overseas s | s ratio | 20\% |

- Brand Portfolio of Brands Under Development

| Company | ACRO INC. | DECENCIA INC. |
| :---: | :---: | :---: |
| Brand | THREE <br> Amplitude FIVEISM | DECENCIA |

[^3]
## Topics

■ Won \#1 best cosmetics awards from major beauty magazines in 2 H
From left : THREE (2 items)
ITRIM
Amplitude
Quarterly net sales (mil. yen)


Quarterly operating income (mil. yen)


1. Highlights of Consolidated Performance
2. Segment Analysis
3. Progress of Mid-term Management Plan
4. Forecasts and Initiatives for Fiscal 2019
5. Appendices

## Progress of 2017-2020 Medium-term Management Plan

【Management Indicators for 2020】

| Net <br> sales | $\mathbf{¥ 2 5 0}$ bil. or higher <br> CAGR $\mathbf{3 - 4 \%}$ | OP <br> income | OP margin $15 \%$ or higher <br> CAGR $10 \%$ | ROE | $12 \%$ or higher |
| :--- | :---: | :---: | :---: | :---: | :---: |

( ( mil.) Sales / OP income \& margin

(\%) ROE


> Some of the indicators such as net sales CAGR have already been achieved; however, ROE is temporary declined due to an impact of extraordinary losses.

> The Group aims to achieve the medium-term management plan and make a leap for the next long-term vision in the two years until 2020.

## 【Growth Strategies】

## Strategies

4

5

Bring overseas operations solidly into the black overall

Expand brands under development, create new brands, pursue M\&A activity
Strengthen operations

Enhance capital efficiency and enrich shareholder returns
Sustain stable growth of flagship brands to lead Group earnings (reinforce R\&D, human resources and governance)
and enich shareholder retur

## Evaluation

## Slightly behind

Behind

On track
On track

Slightly behind whitening active ingredient. nomination and compensation. - Realized stable increase in dividends.


- THREE and DECENCIA continue to expand. - Three new brands were launched in September 2018.
- Launch of a skin FOSHU* and approval of new skin
- Establish a voluntary advisory committee for
- ROE temporarily declined due to extraordinary losses.
* Food for Specified Health Uses (FOSHU)


## Priority matters are:

(1) bringing ORBIS back to a sales growth trajectory and
(2) drastically reforming the structure at Jurlique and H2O PLUS for profitability improvement.

1. Highlights of Consolidated Performance
2. Segment Analysis
3. Progress of Mid-term Management Plan
4. Forecasts and Initiatives for Fiscal 2019
5. Appendices

| (mil. yen) | FY2018 | YoY Change |  |
| :---: | :---: | :---: | :---: |
|  | Full-year Results | Amount | \% |
| Consol. net sales | 248,574 | 4,239 | 1.7\% |
| Beauty care | 231,207 | 4,074 | 1.8\% |
| Real estate | 2,707 | 12 | 0.5\% |
| Others | 14,659 | 151 | 1.0\% |
| OP income | 39,496 | 615 | 1.6\% |
| Beauty care | 38,294 | 173 | 0.5\% |
| Real estate | 1,001 | (81) | (7.5\%) |
| Others | 796 | 1,110 | - |
| Reconciliations | (596) | (587) | - |
| Ordinary income | 38,954 | (295) | (0.8\%) |
| Net income attributable to owners of parent | 8,388 | $(18,749)$ | (69.1\%) |


| FY2019 | YoY Change |  |
| :---: | :---: | :---: |
| Full-year Plan | Amount | \% |
| 241,000 | $(7,574)$ | (3.0\%) |
| 236,200 | 4,992 | 2.2\% |
| 2,400 | (307) | (11.3\%) |
| 2,400 | $(12,259)$ | (83.6\%) |
| 40,500 | 1,003 | 2.5\% |
| 40,600 | 2,305 | 6.0\% |
| 800 | (201) | (20.1\%) |
| 100 | (696) | (87.4\%) |
| $(1,000)$ | (403) | - |
| 40,500 | 1,545 | 4.0\% |
| 25,500 | 17,111 | 204.0\% |

Assumed exchange rates : 1.00 AUD $=86 \mathrm{JPY}(\mathrm{PY} 82.59) \quad 1.00 \mathrm{USD}=107 \mathrm{JPY}(\mathrm{PY} 110.43) 1.00 \mathrm{CNY}=16.7 \mathrm{JPY}(\mathrm{PY} 16.71)$
Consolidated net sales and OP income excluding the pharmaceuticals businesses in the Other segment (transfer completed on January 1, 2019)

| Consol. net sales | 236,255 | 241,000 | 4,744 | 2.0\% |
| :---: | :---: | :---: | :---: | :---: |
| Others | 2,340 | 2,400 | 59 | 2.5\% |
| OP income | 38,896 | 40,500 | 1,603 | 4.1\% |
| Others | 196 | 100 | (96) | (49.2\%) |

## POLA ORBIS HOLDINGS

## Forecasts for Fiscal 2019

The Group aims to achieve an increase in OP income for ten consecutive years; however, anticipates a decline in net sales and OP income in 1H based on assumptions below.

| (mil. yen) | FY2019 | YoY Change |  |
| :--- | ---: | :---: | :---: |
|  | H1 Plan | Amount | $\%$ |
| Consol. net sales | 117,000 | $(8,262)$ | $(6.6 \%)$ |
| Beauty care | 114,600 | $(2,373)$ | $(2.0 \%)$ |
| OP income | 20,800 | $(2,303)$ | $(10.0 \%)$ |
| Beauty care | 20,800 | $(1,453)$ | $(6.5 \%)$ |
| Ordinary income | 20,800 | $(1,923)$ | $(8.5 \%)$ |
| Net income <br> attributable to <br> owners of parent | 13,600 | $(1,721)$ | $(11.2 \%)$ |


| FY2019 | YoY Change |  |
| :---: | ---: | ---: |
| H2 Plan | Amount | $\%$ |
| 124,000 | 688 | $0.6 \%$ |
| 121,600 | 7,365 | $6.4 \%$ |
| 19,700 | 3,307 | $20.2 \%$ |
| 19,800 | 3,759 | $23.4 \%$ |
| 19,700 | 3,468 | $21.4 \%$ |
| 11,900 | 18,832 | - |

## Assumptions:

$\checkmark$ Trend of inbound and buyers
$\checkmark$ Impact of the consumption tax hike
$\checkmark$ Impact of transfer of pharmaceuticals business

- 2018 H2: $¥ 6,539 \mathrm{mil}$ (sale) $/ \neq 165 \mathrm{mil}$ (OP income)
- 2018 H 2 : $¥ 6,539 \mathrm{mil}$. (sales) / $¥ 165 \mathrm{mil}$. (OP income)

|  | FY2018 |
| :--- | :--- |
| Shareholder <br> returns | Annual ¥80 |
| Consol. payout ratio $210.9 \%$ |  |
| Capital <br> investment | $¥ 10,514$ million |
| Depreciation | $¥ 7,075$ million |


| FY2019 (plan) |
| :--- |
| Annual $¥ 116$ (Interim $¥ 35$, Year-end $¥ 45$, Commemorative $¥ 36$ ) |
| Consol. payout ratio $100.6 \%$ |
| $¥ 12,000-13,000$ million |
| $¥ 7,000-8,000$ million |

## Establish brand presence in the global market

## Japan

## Expand repeat customers

Improve repeat ratio and build a customer base that works as the foundation for stable growth


## Increase stores

Develop new customers primarily in China

Expand Wrinkle Shot overseas and on EC
Introduce quasi-drug products that are blended with new skin whitening active ingredient

$\begin{array}{cc}\text { O. } & \text { Review on price difference between } \\ \text { - } & \text { Japan and overseas }\end{array}$

Reinforce collaborated promotions between Japan and overseas

| 0 | 0 |
| :---: | :---: |
|  | 0 |
| 0 | $\frac{0}{2}$ |

U
$\frac{\text { U }}{0}$
$\frac{\text { Develop borderless channel network between }}{\alpha}$
Japan, inbound and overseas

Sales outlook
2019-2020 Net Sales CAGR


Note: POLA anticipates changes in sales mix in 2019 see right for breakdown of sales growth for FY2019


Initiatives Going Forward - Japan

## Expand customer base and further solidify customer structure

## Strengthen communication related to branding and product value and aim for sustainable brand value improvement

| Customer base |  |
| :---: | :---: | :---: |
| $2017 \quad \rightarrow$ | 2018 |
| Acquired new customers |  |
| through Wrinkle Shot |  |$\quad$ \# of existing customers

## Potential needs

Change in survey results from 2015 to 2018 Favorable image up 12pt Willingness of use up 15pt


POLA

## Enhance brand recognition mainly in Asia with the Chinese market as a priority

## $¥ 15.0$ bil. net sales with 100 stores in 2020

- Expand physical touchpoint with customers
- Introduce Wrinkle Shot at a larger scale (launch on cross-border EC is planned in April)


Enhance brand recognition by utilizing both expanding store network around China and e-commerce
\# of high prestige stores
Dec. 2018: $50 \rightarrow \underline{2020: 100}$
(of which, $15 \rightarrow 40$ in China)

## Overseas sales

$¥ 15.0$ bil.


## Strengthen brand communication centered on products for the growth

## 2019 - 2020 : Net Sales CAGR 2-3\% and 20\% OP margin

■ Actively invest in "DEFENCERA", the first FOSHU* product for skin that became available in Japan
*Foods for Specified Health Uses
$\checkmark$ "Prevents skin moisture from escaping"
$\checkmark$ A skincare product certified as FOSHU*
$\checkmark$ Temporary supply shortage occurred due to better-thanexpected sales progress since the launch in January


## Strategic alliance

- Improve brand awareness and expand the business rapidly in the Chinese market
"DEFENCERA"
to be sold on
Tmall end Feb.
- Reform customer communication

Catalog delivery
Point bargains

Develop personalized
app

Sales structure improvement Maximize LTV

## Fundamentally review on business structure and stop increase in losses

## Although some temporary costs will be incurred in the course of reform, Jurlique strives to turn profitable after 2020



1 Reduction in marketing expenses

- Close unprofitable stores in China and reorganize unprofitable business
- Concentrate business resources on Australia and Hong Kong as the key markets and narrow down SKU

2 Reduction in personnel expenses

- Downsize by reviewing the function and structure of the organization

3 Reduction and efficiency improvement of admin. expenses

■ One-off cost incurred in 2018 (allowance for doubtful acc, approx. $¥ 1,600$ mil.)
■ Operation of the Japanese business has been passed on to POLA

- Review on the business model in China

Further enhance brand value of THREE; new brands to become next drivers


## Enhance brand value and cultivate points of contact with new customers

## DECENCIA

- Expand channels (department stores and flagship stores)
$\checkmark$ Diversify touchpoints
$\checkmark$ Strengthen customer intimacy in the brand that is not only limited to functional value
- Reform digital marketing strategy
$\checkmark$ Timely respond to change in the environment of online advertising
$\checkmark$ Outsource operation function and focus on direction


Product lineup expansion
Left : ayanasu base makeup items (September 2018) Right: ayanasu cleansing \& wash (April 2019)

## Business structure reform for the growth after 2020

## H2O+

beauty

- Review on sales channel to reduce losses $\checkmark$ Withdraw from wholesale in North America $\checkmark$ Focus on online and amenity business
- Launch new products developed and manufactured by POLA CHEMICAL



## 3-Step System

1.Elements Keep It Fresh Cleanser 2.Oasis Hydrating Beauty Essence 3.Oasis Hydrating Treatment INDUSTRIES, INC.

Strengthen Operations (R\&D and Governance)

## Research \& Development

Expand new business opportunities by activities of the research organization (MIRC) established in POLA ORBIS HOLDINGS INC. and lead to open innovation

- Continue to boost R\&D investment
- Plan to increase expenditure ratio to sales by $20 \%$ in 2020 compared with 2018 (in beauty care business)
- Ensure sustainable creation of new material pipelines
201720182019 onward
"Wrinkle Shot Serum", anti-wrinkle cosmetics

"DEFENCERA", skin FOSHU
New skin whitening active ingredient

New pipelines
Launched 2019

## Governance

- The Group has established voluntary advisory committees on management nomination, appointment and remuneration (from January 2019)
- For the executive remuneration system, the Group plans to form a system that enhances commitment to business performance


## Improvement of shareholder return

Change in policy on shareholder return
With a policy of consolidated payout ratio of $60 \%$ or higher, enhance shareholder return by realizing stable profit growth.
From a liquidity perspective, the Company will not conduct purchases of treasury stock for the time being and strives to enrich shareholder returns in the form of cash dividends.

With a policy of consolidated payout ratio of 60\% or higher, enhance shareholder return by realizing stable profit growth.
Purchases of treasury stock shall be considered based on our investment strategies, as well as market prices and liquidity of the Company's shares.

90th anniversary commemorative dividend
Dividend forecast for fiscal 2019

Ordinary dividend $¥ 80$
(Consol. payout ratio 69.4\%)
Commemorative dividend $¥ 36$

Annual dividend $¥ 116$ per share
(Consol. Payout ratio 100.6\%)
Dividend yield to be around 4\%
(including shareholder benefit program)


Received approval for quasi-drug products with a new skin whitening active ingredient for the first time in about 10 years; products to be launched in May 2019 from POLA
"Suppresses melanin accumulation and prevents spots and freckles" as efficacy claim, a totally different mechanism from the existing claim of "Suppresses melanin production and prevents spots and freckles"

The Group introduces a new solution for skin whitening


Facial lotion and emulsion with the price of $¥ 11,000$ (excluding tax) each will be added to "POLA White Shot Series" *
Advertising and promotions to be planned for the launch
*Sales target is undecided and not factored into the 2019 guidance as of February 13, 2019
[Reference] Annual sales of White Shot Series in 2018 : approx. $¥ 7.0$ billion (cosmetics products only)

1. Highlights of Consolidated Performance
2. Segment Analysis
3. Progress of Mid-term Management Plan
4. Forecasts and Initiatives for Fiscal 2019
5. Appendices

## (Appendix) About POLA ORBIS Group

## Beauty care is the core business of the Group, and 9 different cosmetics brands are operated under the Group umbrella

Beauty care business 93\%
Real estate business 1\%
Other businesses 6\% (dermatological drugs and building maintenance business)


## Our strengths

- Multi-brand strategy
- Focus on skincare products
- Flagship brands, POLA and ORBIS own and operate through their own unique sales channels

■ Meeting diversified needs of customers
■ High customer repeat ratio
■ Strong relationships with customers

|  | Sales ratio* | Brand | Concept and products | Price | Sales channel |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Flagship brands | 65\% | $\square \square$ <br> Since 1929 | - High-prestige skincare <br> ■ Leading-edge technology in anti-aging and skin-whitening fields | Approx. ¥10,000 or higher | - Consignment sales through Beauty Directors, department store counters and online <br> - Overseas, duty free stores |
|  | 22\% | ORBIS <br> Since 1984 | Anti-aging brand to draw out people's intrinsic beauty | Approx. <br> $¥ 1,000 \sim$ <br> $¥ 3,000$ | ■ Mail-order (online and catalog) <br> - Directly-operated stores <br> - Overseas |
| Overseas Brands | 4\% | Jurlique <br> Acquired in 2012 | - Premium natural skincare brand from Australia | Approx. $¥ 5,000$ <br> or higher | Department store counters, directlyoperated stores, and online <br> Duty free stores |
|  | 1\% | H2O+ <br> BEAUTY <br> Acquired in 2011 | Skincare with concept of innovation and power of pure water | Approx. $¥ 4,000$ not sold in Japan | ■ US: Specialty stores and online |
| Brands <br> under <br> develop -ment | 8\% | T H R E E <br> Since 2009 | - Skincare made with natural ingredients from Japan and fashion-forward make-up | Approx. $¥ 5,000$ or higher | - Department store counters and specialty stores <br> - Directly-operated stores and online <br> - Overseas and duty free stores |
|  |  | Amplitude Since 2018 | - High prestige quality makeup from Japan | Approx. <br> ¥5,000~ <br> $¥ 10,000$ | - Department stores and online |
|  |  | Since 2018 | - Premium skincare made from finely selected organic ingredients | Approx. $¥ 20,000$ | ■ Department stores and online |
|  |  | $\begin{gathered} \text { FIVEISM } \\ \times \times \text { THEE } \\ \text { Since } 2018 \\ \hline \end{gathered}$ | Industry's first men's cosmetics focusing on makeup | Approx. <br> ¥2,000~ <br> $¥ 12,000$ | - Department stores, directly-operated stores <br> - Online |
|  |  | DECENCIA <br> Since 2007 | ■ Skincare for sensitive skin | Approx. $\begin{gathered} ¥ 2,000 ~ \\ ¥ 5,000 \end{gathered}$ | - Online |

## POLA ORBIS (Appendix) Improvement in Capital Efficiency and <br> HOLDINGS Shareholder Returns

Initiatives to Improve Capital Efficiency


## Improvement of Shareholder Return

## Basic Policy :

- With a policy of consolidated payout ratio of $\mathbf{6 0 \%}$ or higher, enhance shareholder return by realizing stable profit growth
- Purchases of treasury stock shall be considered based on our investment strategies, as well as market prices and liquidity of the Company's shares

Dividends forecast for FY2019:

- Dividend per share : $¥ 116$
(Interim $¥ 35$, Year-end $¥ 45$, Commemorative $¥ 36$ )
- Consol. payout ratio : 100.6\%



## STAGE3



## POLA ORBIS

## (Appendix) 2017 - 2020 Medium-term Management Plan

## The final stage of the long-term vision for 2020.

Aim to improve profitability in Japan, promote a solid shift toward overall profitability from overseas operations and build a brand structure for next-generation growth.

Consolidated net sales
■ Consol. net sales:

$$
\begin{aligned}
& \text { CAGR } 3 \text { to } 4 \% \\
& (¥ 250.0 \text { bil. in FY2020) }
\end{aligned}
$$

Operating income

- Operating income:

CAGR 10\% or higher
■ Operating margin: $15 \%$ or higher in FY2020

Capital efficiency

- Target for ROE: $12 \%$ in FY2020


## Shareholder returns

■ Consolidated payout ratio: 60\% or higher
from FY2017


```
Strategy 3. Expand brands under development, create new brands, pursue M\&A activity
```

Strategy 4. Strengthen operations (reinforce R\&D, human resources and governance)

Strategy 5. Enhance capital efficiency and enrich shareholder returns

## POLA ORBIS (Appendix) Beauty Care Business Results <br> HOLDINGS for FY2016 - FY2018 by Brands

| (mil. yen) | FY2016 Results | FY2017 <br> Results | FY2018 Results | 2017 vs 2018 YoY Change |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Amount | \% |
| Consolidated net sales | 218,482 | 244,335 | 248,574 | 4,239 | 1.7\% |
| Beauty care net sales | 202,446 | 227,133 | 231,207 | 4,074 | 1.8\% |
| POLA | 116,126 | 144,012 | 150,183 | 6,170 | 4.3\% |
| ORBIS | 55,857 | 53,066 | 51,051 | $(2,014)$ | (3.8\%) |
| Jurlique | 13,118 | 12,772 | 10,386 | $(2,385)$ | (18.7\%) |
| H2O PLUS | 2,547 | 2,303 | 2,041 | (261) | (11.4\%) |
| Brands under development | 14,796 | 14,978 | 17,544 | 2,566 | 17.1\% |
| Consol. operating income | 26,839 | 38,881 | 39,496 | 615 | 1.6\% |
| Beauty care operating income | 25,904 | 38,121 | 38,294 | 173 | 0.5\% |
| POLA | 16,993 | 28,584 | 32,574 | 3,989 | 14.0\% |
| ORBIS | 11,279 | 9,080 | 9,340 | 259 | 2.9\% |
| Jurlique | $(1,183)$ | (505) | $(3,763)$ | $(3,257)$ | - |
| H2O PLUS | $(2,027)$ | (317) | (552) | (235) | - |
| Brands under development | 841 | 1,278 | 695 | (583) | (45.6\%) |

Note : Consolidated operating income and loss for each brand are shown for reference purpose only (figures are unaudited)


[^0]:    Note: Consolidated operating income and loss for each brand are shown for reference purposes only (figures are unaudited)

[^1]:    (1) Mail-order includes online and other mail-order

    * YoY basis
    (2) For the last 6 months period (3) Series consists of ORBIS $U, U$ encore, and $U$ white

[^2]:    (1) For operating income, the YoY difference is shown as an amount (mil. yen) (2) USD basis, YoY

[^3]:    Note: Apart from the portfolio above, Brands Under Development includes the OEM business.

